AzTrials
AzTrials

ObesityNCT01343017

Impact of Increased Tidal Volumes on Oxygenation and Cardiac Output

A study testing Ventilatory pattern in people with Obesity, run by Region Skane at 1 site in Sweden.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

General anaesthesia impairs respiratory function in overweight patients. The investigators wanted to compare arterial concentration of sevoflurane and oxygen in overweight patients ventilated with increased tidal volume, or normal tidal volume with added 10 cm H2O PEEP. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Obesity
What is being tested?
Ventilatory pattern
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteSweden
Study dates
Sep 2010to Apr 2011
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • ASA physical status 1 or 2
  • Scheduled for elective colon surgery
  • Body mass index more than 25 kg/m2

Who cannot join

  • Patients with known pulmonary or cardiovascular disease

Trial locations and contacts

1 site in 1 country.

Sweden1 site
  • Department of Anaesthesia and Intensiv Care, Faculty of Medicine Lund University

    Lund, Lund, SE-221 85

Other trials in Sweden

About this study

Official title: Increased Tidal Volume During Anaesthesia Compared to PEEP. Impact on Arterial Concentration of Sevoflurane, Oxygenation and Cardiac Output in a Randomised Clinical Study of Overweight Patients.

General anaesthesia impairs respiratory function in overweight patients. The investigators wanted to compare arterial concentration of sevoflurane and oxygen in overweight patients ventilated with increased tidal volume, or normal tidal volume with added 10 cm H2O PEEP.

Read the detailed description

Functional residual capacity (FRC) and pulmonary gas exchange decrease during induction of general anaesthesia due to closure of airways and genesis of atelectasis. It has been demonstrated that there is a correlation between body constitution and airway closure under general anaesthesia with mechanical ventilation. In the supine position, FRC and respiratory compliance decrease more with an increased body mass index (BMI). In morbidly obese patients general anaesthesia and paralysis lead to even more atelectasis and an increased risk of hypoxemia. In about 90 % of all patients ventilated without positive end-expiratory pressure (PEEP) atelectases are formed, which contribute to impairment of gas exchange. Atelectasis formation can be reduced by PEEP but increasing intrathoracic pressure with PEEP, impairs the venous return to the heart, which reduces stroke volume and cardiac output.

In previous studies the investigators compared the effects of increased tidal volume (VT) with zero end-expiratory pressures (ZEEP) on oxygenation and arterial concentrations of sevoflurane. The investigators found moderately improved oxygenation and a reduced difference between arterial and exhaled carbon dioxide tension with larger tidal volumes achieved this way. The results were similar to what could be expected from an increase in FRC and also included a more efficient uptake of sevoflurane. The investigators have recently confirmed these findings also in overweight patients.

In the present study the investigators will compare arterial concentration of sevoflurane and oxygen in patients with BMI over 25 kg/m2 undergoing abdominal surgery, ventilated with larger tidal volumes or added 10 cmH2O PEEP. The investigators also will assess the influence of these ventilation modes on cardiac output.

Method Ethical approval for this study according to the standards set in the Helsinki declaration (Regional Ethics Committee Dnr: 2009/529 and additions to the application with the measurement of cardiac output Dnr 2010/481) will be provided by Regional Ethics Committee, Lund, Sweden on September 2009 and September 2010. The investigation will include 60 patients, ASA physical status 1 or 2, scheduled for elective colon surgery. Patients will be considered for inclusion in the trial if they will be over 18 yr age and have a BMI more than 25 kg/m2. All procedures will be estimated to last more than 60 minutes. Consent to participate in the study will be received from each patient. Patients with known pulmonary or cardiovascular disease will be excluded. Patients will be randomised to one of two groups with 30 patients in each group via randomly mixed sealed envelope assignment at the start of the procedure in the operating theatre. Interim analysis will be performed after 15 + 15 patients.

Experimental procedure Before start of anaesthesia, an unused carbon dioxide absorber will be applied (Drägersorb, Dräger Medical, Lübeck, Germany) to the anaesthesia ventilator (Dräger Primus™, Dräger Medical, Lübeck, Germany). All patients will be preoxygenated with 100% oxygen for 3-4 minutes with a fresh gas flow of 5 liters/minute. Anaesthesia will be induced with 2 µg/kg fentanyl and 1.5-3.0 mg/kg propofol. Rocuronium 0.6 mg/kg will be administered for muscle paralysis. Ventilation will be assisted manually with 100% oxygen via a semiopen circle system (4.5 L volume) until tracheal intubation and then by means of a ventilator with an FiO2 at 0.35 in nitrogen. The respiratory rate will be 15/min throughout the study and VT will be adjusted as to achieve a PETCO2 at 4.5 kPa. No positive end-expiratory pressure (PEEP) will be applied. Propofol 8 mg/kg/h will be infused until an arterial cannula have been inserted in the radial artery. Stroke volume (SV) and cardiac output (CO) will be assessed in 20 patients (10 in each group) with LIDCO Rapid® (LiDCO Ltd, Cambridge, UK). Transoesophageal echocardiography (TEE) will be used to assess cardiac output in 6 patients (3 in each group) with Philips CX-50®, TEE ultrasound X7-2t (Philips Ultrasound, Bothell, WA, USA). After a control (time zero) sample of arterial blood (3 ml) have been obtained, the ventilatory mode will be altered as follows: In the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then VT will be increased until Pplateau will be 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose (disposable plastic tube, Medcore, AB Uppsala, Sweden) placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube. This flexible corrugated hose increased the dead-space volume and provided adjustable rebreathing of carbon dioxide. In the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be applied. When required, VT will be then adjusted to maintain PETCO2at 4.5 kPa. In both groups, inspiratory:expiratory ratio was 1:2 including an inspiratory plateau of 10%. When PETCO2 values will be stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser (sevoflurane Dräger Vapor 2000: Medical, Lübeck, Germany) set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.

Blood samples of 3 ml were drawn from the arterial line into heparinised syringes at 1, 3, 5, 10, 15, 30, 45 and 60 minutes after the start of the sevoflurane administration (totally 27 ml). Arterial oxygen tension (PaO2), oxygen saturation (SaO2) and carbon dioxide tension (PaCO2) will be analysed using an automatic blood gas analyzer (ABL 725™, Radiometer, Copenhagen Denmark). Sevoflurane concentration will be analysed with gas chromatography (GC) on a Perkin-Elmer 3920 gas liquid chromatograph, as previously described.

Patients will be monitored with three-lead ECG, heart rate, oxygen saturation, as measured by pulse oximeter (SpO2) and invasive arterial blood pressure (Solar 8000, General Electric Medical System, Milwaukee, WI, USA). SV and CO were assessed with a LIDCO Rapid® via the arterial catheter. Inspiratory and expiratory oxygen partial pressure (FiO2, PETO2), sevoflurane inspiratory and expiratory partial pressure (Fisevo, PETsevo) and carbon dioxide inspiratory and expiratory partial pressure (FiCO2, PETCO2) will be analysed by the ventilator. Total ventilation per minute, tidal volumes and airway pressures as peak pressure, plateau pressure and mean pressure were measured and documented at the same intervals. Static compliance of the respiratory system will be calculated as tidal volume divided by the inspiratory plateau pressure minus PEEP.

Extra doses of fentanyl (50-100 µg) will be given if mean arterial blood pressure (MAP) increased more than 20% above the initial baseline level. Hypotension (MAP less than 60 mmHg) will be treated with 5-10 mg norepinephrine intravenously. All patients received 3-5 ml/kg/h of glucose solution 2.5% with sodium (70 mmol/l), chloride (45 mmol/l) and acetate (25 mmol/l) intravenously. Neuromuscular blockade will be monitored with a neuromuscular transmission analyzer (TOF-Watch™; Organon Technology B V., Boxel Netherlands). Additional doses of rocuronium were given at the discretion of the anaesthetist.

LiDCO The LiDCO System is a cardiac output monitoring apparatus that uses pulse waveform contour analysis via an arterial catheter. The device uses a proprietary algorithm to analyze the pulse contour by using patient specific data from the patient monitor.16 Linton and colleagues found a good conformity between thermodilutions and LiDCO measurements in 40 patients, with a linear regression value of 0.94.

Transoesophageal echocardiography Stroke volume, cardiac output, and right ventricular function will be assessed using transoesophageal echocardiography. Four and 5-chamber transgastric views will be obtained in all six patients included for TEE. The velocity time integral at the left ventricular outflow tract (VTI LVOT) was measured using pulsed wave Doppler. The diameter of the aorta will be measured using a mid-oesophageal long axis view at the level of the aortic annulus. Measurement of stroke volume will be made by multiplying the LVOT VTI and the aortic diameter. Cardiac output will be calculated by multiplying stroke volume with heart rate. All images will be recorded in triplicate by the same operator and measurements made off-line in a blinded fashion.

Conditions
Obesity
Being tested
Ventilatory pattern
Keywords
Anaesthesia, Pulmonary gas exchange, Functional residual capacity, Cardiac output, Sevoflurane
Medical subject headings
Obesity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ventilatory patternOther

    Also called Increased tidal volume (IVT), Normal tidal volume with PEEP (NVT)

    In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.

Study groups in NCT01343017
Study groupRoleWhat they receive
Increased tidal volume (IVT)OtherIn the group with increased tidal volume (IVT), initial plateau pressure (Pplateau) will be monitored and then tidal volume will be increased until Pplateau was 0.04 cm H2O/kg over the initial Pplateau. The PETCO2 will be then adjusted to 4.5 kPa with a flexible corrugated hose placed between the Y-piece of the anaesthesia circle system and the heat and moisture filter (HME) attached to the endotracheal tube.
Receives: Other: Ventilatory pattern
Normal tidal volume (NVT), with PEEPOtherIn the group with normal tidal volume (NVT), a PEEP to10 cmH2O will be applied. When required, VT will then adjusted to maintain PETCO2 at 4.5 kPa
Receives: Other: Ventilatory pattern

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Increased tidal volumes impact on sevoflurane and oxygenation

    Measured: 60 - 90 minutes

Secondary outcomes (1)
  1. Increased tidal volumes impact on cardiac output

    Measured: 60 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Apr 2011 (estimated)
  2. Study startSep 2010
  3. Primary completionJan 2011
  4. Study completionApr 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Factorial
Masking
Single blind
Who is masked
Participant
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01343017
Sponsor's protocol ID
Dnr 2009/533
Other IDs
EPN 2009/533
Status last verified
Apr 2011
First submitted
26 Apr 2011
Last updated
27 Apr 2011
Results posted
No
Data monitoring committee
No

Publications

  • Enekvist B, Bodelsson M, Sturesson LW, Johansson A. Larger tidal volume increases sevoflurane uptake in blood: a randomized clinical study. Acta Anaesthesiol Scand. 2010 Oct;54(9):1111-6. doi: 10.1111/j.1399-6576.2010.02291.x.

    PubMed 20887413
  • Enekvist BJ, Luttropp HH, Johansson A. The effect of increased apparatus dead space and tidal volumes on carbon dioxide elimination and oxygen saturations in a low-flow anesthesia system. J Clin Anesth. 2008 May;20(3):170-4. doi: 10.1016/j.jclinane.2007.09.013.

    PubMed 18502358
  • Luttropp HH, Johansson A. Soda lime temperatures during low-flow sevoflurane anaesthesia and differences in dead-space. Acta Anaesthesiol Scand. 2002 May;46(5):500-5. doi: 10.1034/j.1399-6576.2002.460505.x.

    PubMed 12027842
  • Sturesson LW, Johansson A, Bodelsson M, Malmkvist G. Wash-in kinetics for sevoflurane using a disposable delivery system (AnaConDa) in cardiac surgery patients. Br J Anaesth. 2009 Apr;102(4):470-6. doi: 10.1093/bja/aep019. Epub 2009 Feb 25.

    PubMed 19244261

Questions about this trial

What is this clinical trial studying?

A study testing Ventilatory pattern in people with Obesity, run by Region Skane at 1 site in Sweden.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Apr 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Increased tidal volumes impact on sevoflurane and oxygenation (time frame: 60 - 90 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01343017, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in